Beilu Pharmaceuticals: Pioglitazone and Metformin oral common release dosage form is expected to be selected for the twelfth batch of centralized procurement.

Beilu Pharmaceutical announced that the company will participate in the twelfth batch of national drug centralized procurement bidding. The product, pioglitazone and metformin oral sustained-release dosage form, is expected to be selected, with the declared specification being 15mg of hydrochloride pioglitazone and 500mg of hydrochloride metformin per tablet. The procurement cycle will start from the date the selection results are executed and last until December 31, 2029.